SEC Form 4 · accession 0001193125-26-381853
Tango Therapeutics, Inc. · TNGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Crystal
Officer — President, R&D
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819133
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 27,000 | $5.20 | A | 142,743 | D | |
| Common StockF2 | Sep 1, 2026 | S | 27,000 | $22.367 | D | 115,743 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $5.20 | Sep 1, 2026 | M | 27,000 | D | — | Mar 1, 2033 | Common Stock | 27,000 | 260,040 | D |
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.